Correlation between the hemoglobin-to-hematocrit ratio and 3-month outcomes in patients with acute ischemic stroke: a secondary analysis based on a prospective cohort study

急性缺血性卒中患者血红蛋白/血细胞比容比值与3个月预后的相关性:基于前瞻性队列研究的二次分析

阅读:1

Abstract

BACKGROUND: Our study dedicated to clarify the connection between the hemoglobin (HB) to hematocrit (HCT) (HB/HCT) ratio and adverse outcomes (AOs) in patients with acute ischemic stroke (AIS) within 3 months. METHODS: A total of 1,906 individuals with AIS were encompassed at a hospital in South Korea. A binary logistic regression model (BLRM) was utilized to explore the linear relationship between the HB/HCT ratio and AOs in patients with AIS. Additionally, generalized additive models (GAMs) and smooth curve fitting were leveraged to investigate the nonlinear relationship between the HB/HCT ratio and AOs in patients with AIS. Two steps recursive method was adopted to calculate the inflection point. RESULTS: There was a nonlinear relationship between the HB/HCT ratio (per 0.01) and AOs in AIS patients according to the GAMS score and smooth curve fitting. The inflection point of the HB/HCT ratio (per 0.01) is 33.191. On the left side of the inflection point, the risk of AOs decreased by 27.80% for every 1 unit increase in the HB/HCT ratio (per 0.01) (odds ratio (OR) = 0.722, 95% confidence interval (CI): 0.577, 0.903, p = 0.004). On the right side of the inflection point, the risk of AOs increased by 20.90% for every 1 unit increase in the HB/HCT ratio (per 0.01) (OR = 1.209, 95% CI: 1.014, 1.440, p = 0.034). CONCLUSION: Our study revealed a U-shaped relationship between the HB/HCT ratio and the prognosis of AIS. Monitoring HB/HCT ratio may be able to identify patients with AOs in advance, ultimately providing more reference of scientific and effective care for AIS patients which may be linked to the improvement of their clinical outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。